Literature DB >> 11199330

Elevated p21 mRNA level in skeletal muscle of DMD patients and mdx mice indicates either an exhausted satellite cell pool or a higher p21 expression in dystrophin-deficient cells per se.

S Endesfelder1, A Krahn, K A Kreuzer, U Lass, C A Schmidt, C Jahrmarkt, A von Moers, A Speer.   

Abstract

Abnormalities in proliferation and differentiation of the dystrophin-deficient muscle are a controversial aspect of the pathogenesis of Duchenne muscular dystrophy (DMD). Analyses of molecules involved in cell cycle modulation do not exist in this context. Cells withdrawn from the cell cycle permanently express p21. The fact that p2 1, in contrast to other cell cycle proteins, is not diminished when myotubes are reexposed to growth media, allocates this cyclin-dependent kinase inhibitor a special function. Here we report for the first time statistically increased p21 mRNA levels in dystrophin-deficient muscle tissue. Only 42% of conventional RT-PCRs from six muscle samples of human controls yielded positive results but almost all skeletal muscle biopsy samples (87%) from DMD patients (n=5). For p21 mRNA quantification in murine muscle samples we were able to use the exact real-time TaqMan PCR method due to generally higher p21 mRNA levels than in human muscles. In addition, contamination with fibroblasts can be excluded for the murine samples because they do not demonstrate fibrosis at the age of 350 days but start to lose their regenerative capacity. In accord with the results in humans, we observed p21 mRNA levels in mdx mice that were approx. four times as high as those in control mice. Elevated p21 mRNA level may indicate a shift in cell composition towards differentiated p21 expressing cells as a result of an exhausted pool of undifferentiated, non-p21-expressing satellite cells due to previous cycles of de- and regeneration. Alternatively, dystrophin-deficient cells per se may express higher p21 levels for unknown reasons. Although we cannot distinguish between these possibilities, the eventual transfec tion of a patient's own satellite cells with p21 antisense oligonucleotides may enable the dystrophic process to be influenced.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11199330     DOI: 10.1007/s001090000153

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  10 in total

1.  CDK inhibitors for muscle stem cell differentiation and self-renewal.

Authors:  Amrudha Mohan; Atsushi Asakura
Journal:  J Phys Fit Sports Med       Date:  2017

2.  CXCL16-mediated cell recruitment to rheumatoid arthritis synovial tissue and murine lymph nodes is dependent upon the MAPK pathway.

Authors:  Jeffrey H Ruth; Christian S Haas; Christy C Park; M Asif Amin; Rita J Martinez; G Kenneth Haines; Shiva Shahrara; Phillip L Campbell; Alisa E Koch
Journal:  Arthritis Rheum       Date:  2006-03

3.  Systemic delivery of allogenic muscle stem cells induces long-term muscle repair and clinical efficacy in duchenne muscular dystrophy dogs.

Authors:  Karl Rouger; Thibaut Larcher; Laurence Dubreil; Jack-Yves Deschamps; Caroline Le Guiner; Gregory Jouvion; Bruno Delorme; Blandine Lieubeau; Marine Carlus; Benoît Fornasari; Marine Theret; Priscilla Orlando; Mireille Ledevin; Céline Zuber; Isabelle Leroux; Stéphane Deleau; Lydie Guigand; Isabelle Testault; Elisabeth Le Rumeur; Marc Fiszman; Yan Chérel
Journal:  Am J Pathol       Date:  2011-09-13       Impact factor: 4.307

4.  Global deletion of BCATm increases expression of skeletal muscle genes associated with protein turnover.

Authors:  Christopher J Lynch; Scot R Kimball; Yuping Xu; Anna C Salzberg; Yuka Imamura Kawasawa
Journal:  Physiol Genomics       Date:  2015-09-08       Impact factor: 3.107

5.  Antisense oligonucleotides and short interfering RNAs silencing the cyclin-dependent kinase inhibitor p21 improve proliferation of Duchenne muscular dystrophy patients' primary skeletal myoblasts.

Authors:  Stefanie Endesfelder; Alexander Kliche; Hanns Lochmüller; Arpad von Moers; Astrid Speer
Journal:  J Mol Med (Berl)       Date:  2004-11-05       Impact factor: 4.599

6.  Transfection of normal primary human skeletal myoblasts with p21 and p57 antisense oligonucleotides to improve their proliferation: a first step towards an alternative molecular therapy approach of Duchenne muscular dystrophy.

Authors:  Stefanie Endesfelder; Sabine Bucher; Alexander Kliche; Regina Reszka; Astrid Speer
Journal:  J Mol Med (Berl)       Date:  2003-05-06       Impact factor: 4.599

7.  RIP2, a checkpoint in myogenic differentiation.

Authors:  Barbara Munz; Eberhard Hildt; Matthew L Springer; Helen M Blau
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

8.  Identification of transcripts from a subtraction library which might be responsible for the mild phenotype in an intrafamilially variable course of Duchenne muscular dystrophy.

Authors:  Marco Sifringer; Birgit Uhlenberg; Stefanie Lammel; Rita Hanke; Benjamin Neumann; Arpad von Moers; Ina Koch; Astrid Speer
Journal:  Hum Genet       Date:  2003-11-05       Impact factor: 4.132

9.  Differential expression of the angiogenic Tie receptor family in arthritic and normal synovial tissue.

Authors:  Shiva Shahrara; Michael V Volin; Matthew A Connors; G Kenneth Haines; Alisa E Koch
Journal:  Arthritis Res       Date:  2002-01-16

10.  Enhanced Energetic State and Protection from Oxidative Stress in Human Myoblasts Overexpressing BMI1.

Authors:  Silvia Dibenedetto; Maria Niklison-Chirou; Claudia P Cabrera; Matthew Ellis; Lesley G Robson; Paul Knopp; Francesco Saverio Tedesco; Martina Ragazzi; Valentina Di Foggia; Michael R Barnes; Aleksandar Radunovic; Silvia Marino
Journal:  Stem Cell Reports       Date:  2017-07-20       Impact factor: 7.765

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.